Evidence map›Paper›PMID 19549737›Full record

Trial reportDiabetes care2009

Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake.

Elif I Ekinci, Georgina Thomas, David Thomas, Cameron Johnson, Richard J Macisaac, Christine A Houlihan, Sue Finch, Sianna Panagiotopoulos, Chris O'Callaghan, George Jerums

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01552954 (Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial), which is not on this map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01552954 phase4completednot on this mapstarted 2012, after this paper: background citation

Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial

TypeinterventionalSponsorSeoul National University Bundang HospitalRan2012 to 2013Enrolled269ConditionsHypertension, Chronic Kidney Disease, MicroalbuminuriaArmsIntensive education of low salt diet
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Effect of longer-term modest salt reduction on blood pressure.The Cochrane database of systematic reviews · 2013
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Salt Restriction in Diabetes.Current diabetes reports · 2015
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Elif I EkinciEndocrine Centre, Austin Health and University of Melbourne, Heidelberg Repatriation Hospital, Heidelberg West, Victoria, Australia. eekinci2002@yahoo.com.au
Georgina Thomas
David Thomas
Cameron Johnson
Richard J Macisaac
Christine A Houlihan
Sue Finch
Sianna Panagiotopoulos
Chris O'Callaghan
George Jerums
Austin Health · AUHeidelberg Repatriation Hospital · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OBJECTIVE This prospective randomized double-blind placebo-controlled crossover study examined the effects of sodium chloride (NaCl) supplementation on the antialbuminuric action of telmisartan with or without hydrochlorothiazide (HCT) in hypertensive patients with type 2 diabetes, increased albumin excretion rate (AER), and habitual low dietary salt intake (LDS; <100 mmol sodium/24 h on two of three consecutive occasions) or high dietary salt intake (HDS; >200 mmol sodium/24 h on two of three consecutive occasions). RESEARCH DESIGN AND METHODS Following a washout period, subjects (n = 32) received 40 mg/day telmisartan for 4 weeks followed by 40 mg telmisartan plus 12.5 mg/day HCT for 4 weeks. For the last 2 weeks of each treatment period, patients received either 100 mmol/day NaCl or placebo capsules. After a second washout, the regimen was repeated with supplements in reverse order. AER and ambulatory blood pressure were measured at weeks 0, 4, 8, 14, 18, and 22. RESULTS In LDS, NaCl supplementation reduced the anti-albuminuric effect of telmisartan with or without HCT from 42.3% (placebo) to 9.5% (P = 0.004). By contrast, in HDS, NaCl supplementation did not reduce the AER response to telmisartan with or without HCT (placebo 30.9%, NaCl 28.1%, P = 0.7). Changes in AER were independent of changes in blood pressure. CONCLUSIONS The AER response to telmisartan with or without HCT under habitual low salt intake can be blunted by NaCl supplementation. By contrast, when there is already a suppressed renin angiotensin aldosterone system under habitual high dietary salt intake, the additional NaCl does not alter the AER response.

Indexed as

AgedAlbuminuriaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzimidazolesBenzoatesBlood PressureCross-Over StudiesDiabetes Mellitus, Type 2Dietary SupplementsFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionMaleAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzimidazolesBenzoatesHydrochlorothiazideSodium ChlorideSodium, DietaryTelmisartan

Identifiers

PMID19549737
PMCPMC2713627
OpenAlexW2117077939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.